CN105142671A - 卡巴他赛和磺基丁基醚β-环糊精的组合物 - Google Patents

卡巴他赛和磺基丁基醚β-环糊精的组合物 Download PDF

Info

Publication number
CN105142671A
CN105142671A CN201380073396.6A CN201380073396A CN105142671A CN 105142671 A CN105142671 A CN 105142671A CN 201380073396 A CN201380073396 A CN 201380073396A CN 105142671 A CN105142671 A CN 105142671A
Authority
CN
China
Prior art keywords
cabazitaxel
compositions
solution
sulfobutylether beta
sbecd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201380073396.6A
Other languages
English (en)
Other versions
CN105142671B (zh
Inventor
瓦莱丽·阿拉霍夫
格热戈什·皮埃特斯基
基肖尔·帕特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Softto Kimmel pharmaceutical company
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Publication of CN105142671A publication Critical patent/CN105142671A/zh
Application granted granted Critical
Publication of CN105142671B publication Critical patent/CN105142671B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种组合物，所述组合物包含：(a)卡巴他赛(cabazitaxel)和(b)磺基丁基醚β-环糊精。这种组合物在水性介质中展现出出乎意料的所需的稳定性，允许在不使用乙醇或表面活性剂的情况下施用治疗剂量的药物。

Description

卡巴他赛和磺基丁基醚β-环糊精的组合物
发明领域
本发明涉及一种组合物，所述组合物包含：(a)卡巴他赛(cabazitaxel)和(b)磺基丁基醚β-环糊精。这种组合物在水性介质中展现出出乎意料的所需的稳定性，因此允许在不需要乙醇和表面活性剂的情况下施用治疗剂量的药物。
发明背景
卡巴他赛，(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(乙酰氧基)-15-{[(2R,3S)-3-{[(叔丁氧基)羰基]氨基}-2-羟基-3-苯基丙酰基]氧基}-1-羟基-9,12-二甲氧基-10,14,17,17-四甲基-11-氧代-6-氧杂四环[11.3.1.03,10.04,7]十七碳-13-烯-2-基苯甲酸酯，是微管抑制剂，其正在被研究用于多种癌症治疗，包括头颈癌、非小细胞肺癌(non-smallcelllungcancer,NSCLC)、小细胞肺癌(smallcelllungcancer,SCLC)、神经胶质瘤(glioma)、膀胱癌、胃和食道癌、乳腺癌以及卵巢癌。已经具体设计卡巴他赛以克服与紫杉醇(paclitaxel)和多西他赛(docetaxel)以及与许多其他抗癌药物相关的多重耐药性(MDR)。
由于其在水中的低溶解度，卡巴他赛的商用制剂采用聚山梨醇酯80(表面活性剂)作为增溶剂并且采用乙醇作为稀释剂。由于这种表面活性剂和乙醇的存在，这种制剂需要给病人以抗组胺药(antihistamine)、皮质类固醇(corticosteroid)和H2拮抗剂事先用药。这种制剂在向病人中输注前还需要两步制备过程。在第一步中，必须将含有卡巴他赛和赋形剂的小药瓶与含有乙醇的另一个小药瓶混合；在第二步中，然后将该混合溶液用盐水或5％葡萄糖稀释。根据其标签，在室温下，剂量给药溶液必须八小时内使用，或者如果冷藏的话，在24小时内使用。两个时间限制包括大约1小时的输注时间。
因此，将会合乎需要的是拥有这样的卡巴他赛制剂：其展现出增加的稳定性；其不需要表面活性剂和/或乙醇的存在；并且其可以以更简单和方便的过程制备。
尽管现有技术已经提出了有关化合物的制剂，如具有取代的环糊精的多西他赛，这种制剂仍然含有乙醇。因此，例如，Young等人(美国专利8,481,511)公开了比例为1:10-150的多西他赛(docetaxel)与羟丙基-β-环糊精或磺基丁基-β-环糊精的包合配合物。该配合物如下制备：通过搅拌将溶解在乙醇中的多西他赛加入至环糊精的水溶液中，直到多西他赛完全溶解；将所述溶液在0.2-04μm微孔膜中过滤，然后通过减压移除乙醇以获得液体形式的包合配合物；或者通过减压移除乙醇，接着移除水，然后干燥以获得固体形式的包合配合物。Young等人强调了其最终组合物中降低的乙醇浓度的益处，指出“低的残留乙醇水平为提高多西他赛稳定性和降低刺激和其他副作用提供了有利的保证”。因此，出乎意料的是，可以使用磺基丁基醚β环糊精制备改进的卡巴他赛制剂，所述制剂不含有任何残留的乙醇。
发明描述
本发明涉及一种组合物，所述组合物包含：(a)卡巴他赛和(b)磺基丁基醚β-环糊精(“SBECD”)。
通常，卡巴他赛与SBECD的重量比在1:30至1:1000之间；优选地，该比例在1:90至1:200之间。在一个特别优选的实施方案中，本发明的组合物包含重量比为大约1:133的卡巴他赛和SBECD。
这种组合物还可以任选地包含加入以提高其药物性能的额外组分。尤其是，可以将酸、碱、和/或盐加入至组合物中以调节组合物的pH和渗涨度(tonicity)。特别优选的是，使用HCl、NaOH、柠檬酸和NaCl调节组合物的pH和渗涨度。
在某些实施方案中，组合物是适于通过静脉内注射或输注施用的无菌液体水溶液并且包含0.5％至70％之间的SBECD，优选1％至40％之间的SBECD，并且更优选2％至20％之间的SBECD。
在其它实施方案中，本发明的组合物是无菌固体冻干物形式，或者是包含2％至70％之间、优选20％至60％之间的SBECD的水溶液形式；所述两种形式均适于储存。
本发明的组合物可以通过将卡巴他赛与SBECD的水溶液混合而制备。通常在室温下将这种组合物混合，尽管可以采用更高或更低的温度。之后通常将混合物过滤并储存。如果需要的话，可以将过滤的溶液冷冻干燥用于储存。
实施例：
实施例1.SBECD水溶液中的卡巴他赛溶解度
将过量的卡巴他赛与SBECD水溶液在23℃混合16小时。将所得到的悬浮液通过0.22μm滤器过滤，并且通过HPLC分析澄清的滤液溶液。卡巴他赛在溶液中的浓度在以下表中给出。
表.在23℃下在SBECD水溶液中卡巴他赛的平衡溶解度
实施例2.SBECD水溶液中卡巴他赛溶液的稳定性
通过先后将SBECD溶解在水中并且将卡巴他赛溶解在所得到的溶液中，接着通过0.22μm滤器过滤，制备在20％SBECD水溶液中的含有2.02mg/mL卡巴他赛的溶液。随后用水将部分溶液稀释以分别形成包含1％、4.8％和10％SBECD的三种溶液。将溶液在温度23℃下温育并且在选定的时间点使用HPLC分析。结果在以下表中给出。所有溶液都是稳定的。
表.在使用不同稀释度的具有SBECD的水性组合物中的卡巴他赛浓度
实施例3.20％SBECD水溶液中的卡巴他赛溶液的制备
将2180mg的SBECD溶解在8707mg的蒸馏水中。将16.4mg卡巴他赛加入至该溶液中并且混合直到完全溶解。将溶液通过0.22μm滤器过滤。
实施例4.卡巴他赛和SBECD的冻干组合物的制备
使用干冰将实施例3的溶液快速冷冻。将冷冻的材料冷冻干燥。
实施例5.卡巴他赛组合物在等渗NaCl溶液中的恢复(reconstruction)。
将9.80mL的0.9％NaCl水溶液加至200mg的实施例3的冻干组合物中。将混合物轻轻地混合以制备澄清溶液，所述溶液包含0.15mg/mL卡巴他赛在2％SBECD中的溶液以及0.9％NaCl。
实施例6.药物代谢动力学
雌性Sprague-Dawley大鼠，每组8只动物，接受1小时实施例3的溶液或者等同于卡巴他赛的商用组合物的包含卡巴他赛、聚山梨醇酯80、乙醇和水的溶液的静脉内(i.v.)输注。两种组合物都以剂量8mg/kg施用。在输注开始之后0.5、1、1.08、1.25、1.5、2、3、和4小时收集血液样品；在取样期间从每只动物获取三个样品。使用HPLC测定每个样品中的卡巴他赛的血浆水平。结果在以下表中给出。
结果表明，实施例3的溶液和等同于卡巴他赛的商用组合物的溶液提供相等的对卡巴他赛的暴露(exposure)。
实施例7.在3LL模型中的功效
用鼠3LL细胞(200,000个)静脉内接种C57BL/6小鼠，并且在接种后第1、4和7天用10mg/kg的实施例3的溶液或者等同于卡巴他赛的商用组合物的包含卡巴他赛、聚山梨醇酯80、乙醇和水的溶液的静脉内注射进行治疗。在对照组中使用盐水注射。记录小鼠体重以评价对治疗的耐受性。没有记录到死亡。在第18天时将动物处死并且对肺中的转移进行计数。结果在以下表中给出。
实施例8.在MDA-MB231模型中的功效
将在含有30％基质胶(Matrigel)的细胞培养基中的MDA-MB-231细胞(每个部位500,000个细胞)皮下接种在裸Balb/c小鼠的肋腹(在中肋腹中)的2侧。在第16天后，当肿瘤达到0.5-0.8cm时，将动物随机分为三组并且在第1、4和7天用盐水(对照)治疗，或者用7.5mg/kg的实施例3的溶液或等同于卡巴他赛的商用组合物的包含卡巴他赛、聚山梨醇酯80、乙醇和水的溶液治疗。在研究期间记录肿瘤尺寸和体重，并且在研究结束时移出肿瘤并称重。结果在以下表中给出。
实施例9.在DU-145模型中的功效
将在含有50％基质胶的细胞培养基中的人前列腺癌(prostatecarcinoma)DU-145细胞(每个部位2,000,000个细胞)皮下接种在SCID小鼠的中肋腹的2侧。在第21天后(当肿瘤达到0.5-0.8cm时)将动物随机分为三组并且在此之后第1、4和7天用盐水(对照)治疗，或者用7.5mg/kg的实施例3的溶液或等同于卡巴他赛的商用组合物的包含卡巴他赛、聚山梨醇酯80、乙醇和水的溶液治疗。记录肿瘤尺寸和体重。结果在以下表中给出。

Claims (11)

1.一种组合物，所述组合物包含：(a)卡巴他赛和(b)磺基丁基醚β-环糊精。
2.根据权利要求1所述的组合物，其中卡巴他赛:磺基丁基醚β-环糊精的重量比在1:30至1:1,000之间。
3.根据权利要求2所述的组合物，其中卡巴他赛:磺基丁基醚β-环糊精的重量比在1:90至1:200之间。
4.根据权利要求1所述的组合物，其中所述组合物为适于静脉内注射或输注的水溶液形式，包含以重量计0.5％至70％之间的磺基丁基醚β-环糊精。
5.根据权利要求4所述的组合物，其中所述组合物为水溶液形式，包含以重量计1％至40％之间的磺基丁基醚β-环糊精。
6.根据权利要求5所述的组合物，其中所述组合物为水溶液形式，包含以重量计2％至20％之间的磺基丁基醚β-环糊精。
7.根据权利要求1所述的组合物，其中所述组合物为固体冻干物形式。
8.根据权利要求1所述的组合物，其中所述组合物为适于储存的水溶液形式，包含以重量计2％至70％之间的磺基丁基醚β-环糊精。
9.根据权利要求1所述的组合物，其中所述组合物为适于储存的水溶液形式，包含以重量计20％至60％之间的磺基丁基醚β-环糊精。
10.根据权利要求1所述的组合物，其中所述组合物不含任何乙醇。
11.根据权利要求1所述的组合物，其中所述组合物不含任何表面活性剂。
CN201380073396.6A 2012-12-24 2013-12-23 卡巴他赛和磺基丁基醚β-环糊精的组合物 Active CN105142671B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261848172P 2012-12-24 2012-12-24
US61/848,172 2012-12-24
PCT/IB2013/003255 WO2014122498A2 (en) 2012-12-24 2013-12-23 Cabazitaxel composition

Publications (2)

Publication Number Publication Date
CN105142671A true CN105142671A (zh) 2015-12-09
CN105142671B CN105142671B (zh) 2018-09-14

Family

ID=51300216

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380073396.6A Active CN105142671B (zh) 2012-12-24 2013-12-23 卡巴他赛和磺基丁基醚β-环糊精的组合物

Country Status (16)

Country Link
US (1) US9919053B2 (zh)
EP (1) EP2934593B1 (zh)
JP (1) JP6498610B2 (zh)
KR (1) KR102161866B1 (zh)
CN (1) CN105142671B (zh)
AU (1) AU2013377404B2 (zh)
BR (1) BR112015015202B8 (zh)
CA (1) CA2900508C (zh)
DK (1) DK2934593T3 (zh)
ES (1) ES2771423T3 (zh)
HU (1) HUE048505T2 (zh)
MX (1) MX371067B (zh)
PL (1) PL2934593T3 (zh)
PT (1) PT2934593T (zh)
RU (1) RU2678772C2 (zh)
WO (1) WO2014122498A2 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108066774A (zh) * 2018-01-11 2018-05-25 广州市卓源医药科技有限公司 一种注射用卡巴他赛组合物及其制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018109731A1 (en) * 2016-12-16 2018-06-21 Orbicular Pharmaceutical Technologies Private Limited Pharmaceutical compositions of taxane and its derivatives
WO2020019363A1 (zh) * 2018-07-25 2020-01-30 比卡生物科技（广州）有限公司 一种注射用多西他赛组合物及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100041625A1 (en) * 2006-09-12 2010-02-18 Nanjing Huge-Ring Medicine Technology Development Co., Ltd. Pharmaceutical composition comprising cyclodextrin paclitaxel inclusion and preparation method thereof
US20100048685A1 (en) * 2006-09-12 2010-02-25 Yong Ren Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process
US20120058971A1 (en) * 2009-11-23 2012-03-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2463687A1 (en) * 2001-10-18 2003-04-24 Decode Genetics Ehf Cyclodextrin complexes
JP2005022989A (ja) * 2003-06-30 2005-01-27 Otsuka Pharmaceut Factory Inc 可溶化または分散化された難溶性化合物を含む組成物
KR101137785B1 (ko) * 2003-07-18 2012-04-25 백스터 인터내셔널 인코포레이티드 제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물
CA2543443A1 (en) * 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
KR101502533B1 (ko) * 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
WO2013024495A1 (en) * 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100041625A1 (en) * 2006-09-12 2010-02-18 Nanjing Huge-Ring Medicine Technology Development Co., Ltd. Pharmaceutical composition comprising cyclodextrin paclitaxel inclusion and preparation method thereof
US20100048685A1 (en) * 2006-09-12 2010-02-25 Yong Ren Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
US20120058971A1 (en) * 2009-11-23 2012-03-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAMADA ET AL: "Enhancement of Water-Solubility and Bioactivity of Paclitaxel Using Modified Cyclodextrins", 《JOURNAL OF BIOSCIENCE AND BIOENGINEERING》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108066774A (zh) * 2018-01-11 2018-05-25 广州市卓源医药科技有限公司 一种注射用卡巴他赛组合物及其制备方法
WO2019136817A1 (zh) * 2018-01-11 2019-07-18 比卡生物科技（广州）有限公司 一种注射用卡巴他赛组合物及其制备方法
CN108066774B (zh) * 2018-01-11 2023-04-18 比卡生物科技（广州）有限公司 一种注射用卡巴他赛组合物及其制备方法

Also Published As

Publication number Publication date
KR102161866B1 (ko) 2020-10-05
BR112015015202B1 (pt) 2021-12-21
PL2934593T3 (pl) 2020-05-18
JP2016508138A (ja) 2016-03-17
WO2014122498A3 (en) 2014-12-04
RU2015130495A (ru) 2017-01-27
CN105142671B (zh) 2018-09-14
EP2934593A4 (en) 2016-08-10
AU2013377404A1 (en) 2015-07-30
RU2678772C2 (ru) 2019-02-01
DK2934593T3 (da) 2020-02-17
PT2934593T (pt) 2020-03-09
BR112015015202A2 (pt) 2017-07-11
US20150328321A1 (en) 2015-11-19
MX371067B (es) 2020-01-15
CA2900508C (en) 2021-04-13
AU2013377404A2 (en) 2015-08-27
BR112015015202B8 (pt) 2022-02-15
MX2015008225A (es) 2016-07-20
CA2900508A1 (en) 2014-08-14
AU2013377404B2 (en) 2018-08-23
WO2014122498A2 (en) 2014-08-14
KR20150127035A (ko) 2015-11-16
US9919053B2 (en) 2018-03-20
JP6498610B2 (ja) 2019-04-10
HUE048505T2 (hu) 2020-07-28
EP2934593A2 (en) 2015-10-28
ES2771423T3 (es) 2020-07-06
EP2934593B1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
Kar et al. Current developments in excipient science: implication of quantitative selection of each excipient in product development
TW457095B (en) Pharmaceutical formulations comprising epothilones and lyophilised compositions comprising epothilones
JP5185488B2 (ja) ２−（４−イソブチルフェニル）プロピオン酸の医薬組成物
US20210177845A1 (en) Pde9 inhibitors for treating sickle cell disease
CN104042567A (zh) 一种蛇葡萄素纳米胶束及其应用
CN107106485A (zh) 甲氨蝶呤制剂
CN105142671A (zh) 卡巴他赛和磺基丁基醚β-环糊精的组合物
RU2398578C2 (ru) Фармацевтическая композиция, содержащая производное таксана, которая предназначена для приготовления инфузионного раствора, способ его приготовления и использование
CN103338782A (zh) 包含表面核仁素的多价合成配体和糖胺聚糖的组合物
CN112823786A (zh) 一种含有美洛昔康的药物组合物及应用
CN107137349B (zh) 一种藤黄酸纳米混悬剂及其制备方法
CN100467024C (zh) 氯诺昔康注射用组合物及其制备方法
US11957758B2 (en) Pharmaceutical composition of docetaxel conjugate and preparation method
TW201215412A (en) Stable pharmaceutical composition
CN101129374B (zh) 长春氟宁药物组合物及其制备方法与应用
CN102210868A (zh) 四氢嘧啶及其衍生物在制备口服吸收促进剂中的应用
RU2236227C1 (ru) Устойчивая фармацевтическая форма противоракового препарата
CN101559037B (zh) 用于静脉和脑内注射的两元溶液型制剂
CN104703626B (zh) 用于治疗癌症的基于碘油的抗肿瘤乳剂
CN101773509A (zh) 高浓度甘草甜素制剂
WO2003099288A1 (fr) Composition medicinale
CN101590029A (zh) 一种丙泊酚组合物
KR20140147336A (ko) 도세탁셀을 함유하는 액상 주사용 조성물
CN114306612A (zh) 非致病性细胞相关组分的应用以及包含非致病性细胞相关组分的药物组合物
CN102552259A (zh) 伊潘立酮的β-环糊精包合复合物及其药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20171121

Address after: Quebec

Applicant after: Softto Kimmel pharmaceutical company

Address before: Quebec

Applicant before: SUPRATEK PHARMA INC.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant